Inavolisib in combination with palbociclib and fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer

Published on 06 Feb 2026
Last Updated on 06 Feb 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended inavolisib, in combination with palbociclib and fulvestrant, for inclusion on the MOH List of Subsidised Drugs for PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine therapy. The decision was based on the unfavourable cost effectiveness compared with palbociclib plus fulvestrant at the proposed price, and the unacceptable price-volume agreement proposed by the company.

Clinical indication, subsidy class and MediShield Life claim limit for inavolisib are provided in the Annex.

Guidance-Inavolisib in combination with palbociclib and fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer (6 Feb 2026)

PES_Inavolisib in combination with palbociclib and fulvestrant for treating PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (6 Feb 2026)